Elective Liver Transplant List Mortality: Development of a United Kingdom End-Stage Liver Disease Score

被引:125
|
作者
Barber, Kerri [1 ]
Madden, Susanna [1 ]
Allen, Joanne [1 ]
Collett, Dave [1 ]
Neuberger, James [1 ]
Gimson, Alexander [2 ]
机构
[1] NHS Blood & Transplant, Bristol BS34 8RR, Avon, England
[2] Cambridge Univ Hosp Fdn NHS Trust, Hepatobiliary & Liver Transplant Unit, Cambridge, England
关键词
Liver transplantation; Transplant list mortality; Allocation; UKELD score; SERUM SODIUM CONCENTRATION; MELD SCORE; PREDICTS MORTALITY; WAITING-LIST; SURVIVAL; MODEL; HYPONATREMIA; CIRRHOSIS; IMPACT; RISK;
D O I
10.1097/TP.0b013e318225db4d
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background. Prediction of short-term survival probability is important in the selection and allocation of patients for liver transplantation, and the Mayo End-Stage Liver Disease (MELD) score has been used in these contexts. The aim of this study was to develop and validate a model for estimation of short-term prognosis of patients selected for elective liver transplantation in the United Kingdom. Methods. A modeling dataset was based on 1103 adult patients registered for a first elective liver transplant in the United Kingdom between April 1, 2003, and March 31, 2006, and a validation dataset based on 452 patients registered between April 1, 2006, and March 31, 2007. The final model (United Kingdom End-Stage Liver Disease) included international normalized ratio, serum creatinine, bilirubin, and sodium. Results. The model, based on the modeling dataset, accurately predicted mortality on the transplant list in the validation dataset and proved to be a better predictor than MELD or MELD-Na. The United Kingdom End-Stage Liver Disease score was not associated with overall posttransplant survival but was associated with both the duration of intensive care unit stay and overall initial hospital stay. Conclusion. This model, developed specifically for patients awaiting liver transplantation, provides a useful tool for the selection of patients for liver transplantation and the allocation of donor livers.
引用
收藏
页码:469 / 476
页数:8
相关论文
共 50 条
  • [31] Delayed Hepatocellular Carcinoma Model for End-Stage Liver Disease Exception Score Improves Disparity in Access to Liver Transplant in the United States
    Heimbach, Julie K.
    Hirose, Ryutaro
    Stock, Peter G.
    Schladt, David P.
    Xiong, Hui
    Liu, Jiannong
    Olthoff, Kim M.
    Harper, Ann
    Snyder, Jon J.
    Israni, Ajay K.
    Kasiske, Bertram L.
    Kim, W. Ray
    HEPATOLOGY, 2015, 61 (05) : 1643 - 1650
  • [32] The Model for End-stage Liver Disease accurately predicts 90-day liver transplant wait-list mortality in Atlantic Canada
    Renfrew, Paul Douglas
    Quan, Hude
    Doig, Christopher James
    Dixon, Elijah
    Molinari, Michele
    CANADIAN JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2011, 25 (07) : 359 - 364
  • [33] Kidney function and mortality post-liver transplant in the Model for End-Stage Liver Disease era
    Sethi, Aastha
    Estrella, Michelle M.
    Ugarte, Richard
    Atta, Mohamed G.
    INTERNATIONAL JOURNAL OF NEPHROLOGY AND RENOVASCULAR DISEASE, 2011, 4 : 139 - 144
  • [34] Model for end-stage liver disease - Did the new liver allocation policy affect waiting list mortality?
    Austin, Mary T.
    Poulose, Benjamin K.
    Ray, Wayne A.
    Arbogast, Patrick G.
    Feurer, Irene D.
    Pinson, Wright
    ARCHIVES OF SURGERY, 2007, 142 (11) : 1079 - 1085
  • [35] VALIDATION OF THE 5-VARIABLE MODEL FOR END-STAGE LIVER DISEASE (5VMELD) FOR PREDICTING MORTALITY ON THE LIVER TRANSPLANT WAITING LIST
    Myers, Robert P.
    Tandon, Puneeta
    Ney, Michael
    Meeberg, Glenda
    Faris, Peter D.
    Shaheen, Abdel Aziz M.
    Aspinall, Alexander I.
    Burak, Kelly W.
    HEPATOLOGY, 2011, 54 : 663A - 663A
  • [36] Could tenofovir modify the model end-stage liver disease (MELD) score in patients with end-stage liver disease eligible for liver transplantation?
    Bruno, Raffaele
    Sacchi, Paolo
    Filice, Gaetano
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2007, 45 (01) : 123 - 123
  • [37] Validation of the five-variable Model for End-stage Liver Disease (5vMELD) for prediction of mortality on the liver transplant waiting list
    Myers, Robert P.
    Tandon, Puneeta
    Ney, Michael
    Meeberg, Glenda
    Faris, Peter
    Shaheen, Abdel Aziz M.
    Aspinall, Alexander I.
    Burak, Kelly W.
    LIVER INTERNATIONAL, 2014, 34 (08) : 1176 - 1183
  • [38] Mind the Model for End-Stage Liver Disease: Model for End-Stage Liver Disease Score as an Indicator of Hemoderivate Transfusion and Survival in Liver Transplantation
    Alonso, I. J.
    Maestro, O. C.
    Gomez, N. F.
    Mateos, R. S.
    Quinto, A. M.
    Molero, F. C.
    Municio, A. M.
    Pulido, J. C.
    Segurola, C. L.
    Romero, C. J.
    TRANSPLANTATION PROCEEDINGS, 2015, 47 (01) : 97 - 99
  • [40] Relationship between model for end-stage liver disease score and left ventricular function in patients with end-stage liver disease
    Sun, Fu-Rong
    Wang, Ying
    Wang, Bing-Yuan
    Tong, Jing
    Zhang, Dai
    Chang, Bing
    HEPATOBILIARY & PANCREATIC DISEASES INTERNATIONAL, 2011, 10 (01) : 50 - 54